Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.63

€1.63

-1.190%
-0.02
-1.190%
€1.00
 
19.07.24 / Tradegate WKN: A3EUNZ / Name: Xortx Therapeutics Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Xortx Therapeutics Inc. Stock

We can see a decrease in the price for Xortx Therapeutics Inc.. Compared to yesterday it has lost -€0.020 (-1.190%).
Currently there is a rather negative sentiment for Xortx Therapeutics Inc. with 0 Buy predictions and 3 Sell predictions..
This results in a negative potential of -38.46% based on a current price of 1.63 € and a target price of 1 € for the stock.
For the coming years our community has positive and negative things to say abot the Xortx Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Xortx Therapeutics Inc. in the next few years

Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

XORTX Reprices Warrants Issued in Connection with Previous Private Placements
XORTX Reprices Warrants Issued in Connection with Previous Private Placements

 

CALGARY, AB - April 30, 2024 - XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on

XORTX Announces Publication of Key Research in ADPKD
XORTX Announces Publication of Key Research in ADPKD

CALGARY, AB – April 22, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company